It will clearly have an impact on the reference pricing system with respect to generics in the F2 group. The entire idea of the bill is to, in a sense, disaggregate them. As I explained in my previous answer, if you do not, the taxpayer and patients will be paying too much for generic drugs. The reference pricing cannot remain for generic drugs, because if it does, the savings to taxpayers and to patients will never occur.